TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02473198
Drug: Femoral Nerve Block Bupivacaine
Normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
Study: NCT02473198
Drug: Toradol
Normalized name: Toradol
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
Study: NCT02473198
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
Study: NCT02590965
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
Study: NCT01328522
Drug: SAR153191 (REGN88)
Normalized name: SAR153191
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Study: NCT04221230
Drug: BTRX-335140
Normalized name: BTRX-335140
DrugBank: BTRX-335140 (DB16068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Drug
Study: NCT00181558
Drug: Atrasentan
Normalized name: ATRASENTAN
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01619566
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
Study: NCT00904657
Drug: sunitinib (Sutent)
Normalized name: sunitinib Oral Capsule [Sutent]
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg capsule Sutent, one application a day for five days
Study: NCT02279108
Drug: indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One injection, 2.5 milligrams per patient, intradermal use
Study: NCT02890784
Drug: dasatinib (SPRYCEL®)
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment optimization for patients with chronic myeloid leukemia (CML)
Study: NCT01009502
Drug: sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
Study: NCT01277159
Drug: A. Control Nerve Block. IV Dexamethasone (4 mg).
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A. Control Nerve Block. IV Dexamethasone (4 mg).
Study: NCT01277159
Drug: B. Nerve Block with Dexamethasone (4 mg). IV saline.
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: B. Nerve Block with Dexamethasone (4 mg). IV saline.
Study: NCT01277159
Drug: C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
Study: NCT01277159
Drug: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
Study: NCT01277159
Drug: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
Study: NCT01148615
Drug: Aflibercept (AVE0005)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT01148615
Drug: Docetaxel (XRP6976)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT01121562
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
Study: NCT00055367
Drug: natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04411914
Drug: Clavulanic Acid
Normalized name: Clavulanic acid
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug will be given in 250mg capsules.
Study: NCT04174612
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2/bid day 1-3 100 mg/m2/die day 4-7
Study: NCT04174612
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/m2/die day 1-3
Study: NCT04174612
Drug: Midostaurin
Normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50 mg/bid day 8-21
Study: NCT04174612
Drug: Cytarabine HD
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m2/bid day 1-3 100 mg/m2/die day 4 1.500 mg bid day 5-7
Study: NCT01241110
Drug: Ofloxacin group A, Azitromycin group B
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.
Study: NCT01241110
Drug: azitromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azitromicin vs ofluxacin
Study: NCT02681510
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard FDA approved 12 weeks of treatment with Varenicline
Study: NCT02681510
Drug: Nicotine Transdermal Patch
Normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
Study: NCT02681510
Drug: Nicotine Mini
Normalized name: Nicotine Mini
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
Study: NCT01783912
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
Study: NCT03404739
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: These patients will be given only one dose of ceftazidime at the start of POEM plus 2 doses of saline solution every 12 hours after the procedure.
Study: NCT03404739
Drug: Ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: These patients will be given ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure.
Study: NCT00079950
Drug: Pegamotecan
Normalized name: Pegamotecan
DrugBank: Pegamotecan (DB12842)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01495702
Drug: Stribild
Normalized name: Stribild
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
Study: NCT01493921
Drug: SR-T100 gel
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be instructed to self-apply approximately 0.3\~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
Study: NCT01516918
Drug: VX-222
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, 400-mg twice daily
Study: NCT01516918
Drug: telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tablet, 1125-mg twice daily
Study: NCT01516918
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet, 1000-mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily
Study: NCT02478879
Drug: ZP-PTH
Normalized name: PTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patch applied daily for 30 minutes, 14 days
Study: NCT02478879
Drug: FORTEO
Normalized name: Forteo
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection administration daily for 14 days
Study: NCT02031419
Drug: CC-122
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg or 3 mg administered orally once daily
Study: NCT02031419
Drug: CC-223
Normalized name: glycerin 0.223 MG/MG
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg or 30mg administered orally once daily.
Study: NCT02031419
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 administered intravenously once every 28 days
Study: NCT02031419
Drug: CC-122
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg or 3mg administered orally once daily.
Study: NCT02031419
Drug: CC-292
Normalized name: BTK inhibitor CC-292
DrugBank: Spebrutinib (DB11764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg twice a day administered orally.
Study: NCT02031419
Drug: CC-223
Normalized name: glycerin 0.223 MG/MG
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg or 30mg per day administered orally daily.
Study: NCT00144157
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00144157
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00144157
Drug: 3TC
Normalized name: 3TC
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00919126
Drug: Xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
Study: NCT00919126
Drug: Xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
Study: NCT00919126
Drug: Medical Air in Oxygen
Normalized name: medical air
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
Study: NCT01341379
Drug: N-carbamylglutamate
Normalized name: N-Carbamylglutamate
DrugBank: Carglumic acid (DB06775)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
Study: NCT02210871
Drug: semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
Study: NCT02848300
Drug: Bimatoprost 1% Formulation A
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
Study: NCT02848300
Drug: Bimatoprost 1% Formulation B
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
Study: NCT02434627
Drug: Sodium Nitrate
Normalized name: Sodium Nitrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given sodium nitrate daily in the form of beetroot juice.
Study: NCT00825955
Drug: Brivanib
Normalized name: Brivanib
DrugBank: Brivanib (DB11958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
Study: NCT00237523
Drug: IoGen (molecular iodine)
Normalized name: Ogen
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03168334
Drug: IDP-123 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Lotion
Study: NCT01726920
Drug: naratriptan
Normalized name: Naratriptan
DrugBank: Naratriptan (DB00952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets containing naratriptan 2,5 mg
Study: NCT00462020
Drug: 5 days of IV antibiotics (ceftriaxone and metronidazole)
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
Study: NCT00462020
Drug: Home with oral antibiotics when eating (ampicillin/clavulanic acid)
Normalized name: Primatene with ephedrine Oral Product
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
Study: NCT00381433
Drug: AVI-4065 Injection
Normalized name: AVI-4065
DrugBank: AVI-4065 (DB05620)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03366207
Drug: Ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.
Study: NCT01873378
Drug: Triptorelin 3.75 mg
Normalized name: triptorelin 3.75 MG
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03035578
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
Study: NCT03035578
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
Study: NCT03453151
Drug: splanchnic nerve anesthesia with a local anesthetic
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)
Study: NCT02734407
Drug: aflibercept 2.0 mg
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
Study: NCT00452556
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly
Study: NCT00452556
Drug: Leuprolide Acetate (Eligard®)
Normalized name: leuprolide acetate Prefilled Syringe [Eligard]
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 years
Study: NCT01105793
Drug: Danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose FP1198 applied once daily to both breasts for 6 treatment cycles.
Study: NCT00051935
Drug: Alglucosidase alfa
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20 mg/kg (qow); intravenous
Study: NCT04366323
Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 80 million adipose-tissue derived mesenchymal stem cells
Study: NCT00475462
Drug: metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01907594
Drug: D-cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01907594
Drug: Nicotine Replacement Therapy (patch)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01461915
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).
Study: NCT01461915
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Following the completion of nab-paclitaxel administration, gemcitabine IV infusion at 1000 mg/m2 will be administered over 30 minutes. Gemcitabine will be administered weekly for 3 weeks followed by 1 week of rest (28-cycle).
Study: NCT01461915
Drug: Dociparstat
Normalized name: Dociparstat sodium
DrugBank: Dociparstat sodium (DB16481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the completion of gemcitabine administration, dociparstat IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration. Immediately following the dociparstat IV bolus administration, dociparstat 48-hour IV continuous infusion at 0.375 mg/kg/hr will be administered.
Study: NCT02260102
Drug: Temocillin
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations \[no change due to enrollment in the study\]).
Study: NCT03930212
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: received rectal progesterone suppositories 400 mg once daily
Study: NCT02077634
Drug: abiraterone acetate + prednisone + LHRH-therapy
Normalized name: Abiraterone Acetate
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hormon therapy will go on
Study: NCT02077634
Drug: abiraterone acetate + prednisone
Normalized name: Abiraterone Acetate
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ormon therapy will be stopped
Study: NCT00586924
Drug: Moxetumomab Pasudotox (CAT 8015)
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study: NCT00586924
Drug: Moxetumomab Pasudotox (CAT 8015)
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study: NCT00586924
Drug: Moxetumomab Pasudotox (CAT 8015)
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study: NCT00586924
Drug: Moxetumomab Pasudotox (CAT 8015)
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study: NCT00586924
Drug: CAT 8015 (Moxetumomab Pasudotox)
Normalized name: Spotted cat
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
Study: NCT00271401
Drug: Abxicimab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no